Evidence map›Paper›PMID 30337627›Full record

ArticleScientific reports2018

Neutralizing antibodies to Severe Fever with Thrombocytopenia Syndrome Virus in general population, Shandong Province, China.

Dexin Li, Lijun Shao, Yu Bi, Guoyu Niu

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Epidemiological Characteristics of Severe Fever with Thrombocytopenia Syndrome.The American journal of tropical medicine and hygiene · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Dexin LiSchool of Public Health and management, WeiFang Medical University, Weifang, 261053, China.
Lijun ShaoSchool of Public Health and management, WeiFang Medical University, Weifang, 261053, China.
Yu BiSchool of Public Health and management, WeiFang Medical University, Weifang, 261053, China.
Guoyu NiuSchool of Public Health and management, WeiFang Medical University, Weifang, 261053, China. niugy@wfmc.edu.cn.
Weifang Medical University · CNChinese Center For Disease Control and Prevention · CNNational Institute for Viral Disease Control and Prevention · CN

Funding

Natural Science Foundation of Shandong Province (Shandong Provincial Natural Science Foundation) ZR2016CL03
6 · The paper itself

Abstract

Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious disease caused by SFTS virus (SFTSV) in East Asia. The research on seroprevalence of SFTSV in healthy people and risk factors had been detailed. However, the levels of neutralizing antibodies against SFTSV in general population were currently unclear. In the present study, we tested 1375 healthy persons from Penglai County, eastern China, for SFTSV neutralizing antibodies; 0.58% (8/1,375) was positive and the positive rates were not significantly different among people at different age groups, occupations and genders. Besides, a follow-up study was conducted and the titer of neutralizing antibodies decreased over time in all eight people but one, and the neutralizing antibodies of five lasted for the entire study period of seven years. Our results suggesting that subclinical infection or a relatively mild form of SFTS illness is occurring in this population, but a small percentage of sera have neutralizing capacity to SFTSV. Hence, most people are just susceptible to SFTSV infection.

Indexed as

AdolescentAdultAgedAged, 80 and overAntibodies, NeutralizingBunyaviridae InfectionsChildChild, PreschoolChinaFemaleFollow-Up StudiesHumansInfantInfant, NewbornMaleMiddle AgedAntibodies, Neutralizing

Identifiers

PMID30337627
PMCPMC6193936
OpenAlexW2898073955

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.